spleen

脾脏
  • 文章类型: Journal Article
    Characteristics of livers and spleens of people with multiple sclerosis (pwMS) could constitute good biomarkers of MS-related characteristics such as the disability status. To test the hypothesis \"the gross anatomical features of livers and spleens, are not similar between pwMS with different disease characteristics\" a cross-sectional study was conducted on pwMS seen at the Isfahan MS clinic, Iran, from February until December 2023. Definitive, otherwise-healthy, pwMS were enrolled after an initial laboratory evaluation. Presence/absence and grading of non-alcoholic fatty liver disease (NAFLD) and the span of spleen were determined by a radiologist using high-resolution abdominopelvic ultrasonography. 193 pwMS (160 women) were enrolled. Of whom, 143 (74.1%) were receiving first-line disease-modifying therapies (DMTs), 24 (12.4%) fingolimod, and 26 (13.5%) rituximab. The span of spleen was negatively associated with EDSS (adjusted β [SE] - 4.08 [1.52], p < 0.01), as well as 6 m-CDW (adjusted β [SE] - 6.94 [3.56], p = 0.05), unlike age, DMTs, and MS duration (all with p > 0.05). Receiver operating characteristic analysis showed, spleen span performs significant but poor in discrimination of EDSS > 1 from EDSS = 1 (area under curve [AUC] 0.62, SE 0.05, p < 0.01), yet, significant and fair in discrimination of presence from absence of 6 m-CDW (AUC 0.72, SE 0.06, p < 0.01). Other findings were unremarkable. Further longitudinal, prospective studies are warranted to confirm whether smaller spleens are predictive of higher disability accrual rate in pwMS. Particularly, findings require further validation in untreated/treatment-naïve pwMS, and ones with higher EDSS scores.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:钝性脾损伤(BSI)的非手术治疗(NOM)在适当的患者中被广泛接受。脾动脉栓塞术(SAE)在高级别损伤中可能在增加NOM的成功率中起重要作用。我们以前实施了一项协议,要求转诊所有接受NOM的BSIIII-V级SAE。目前尚不清楚并发症的风险以及纵向结果。我们旨在检查该方案的脾残率和安全性。我们假设脾抢救率会很高,并发症会很低。
    方法:在我们的1级创伤中心进行了为期9年的回顾性研究。收集了维持BSIIII-V级的患者的损伤特征和结果。比较NOM方案(SAE)和非方案(无血管造影或血管造影但无栓塞)的结果。检查血管造影的并发症。
    结果:在2010年1月至2019年2月之间,570名患者患有III-V级BSI。在359(63%)中尝试了NOM,总抢救率为91%(328)。其中,305个符合协议,54个不符合协议(41个没有血管造影,13个没有血管造影,但没有SAE)。在学习期间,对于每一个级别的损伤,与非协议组相比,在协议组中观察到较高的抢救率(III级,97%(181/187)与89%(32/36),四级,91%(98/108)与69%(9/13)和V级,80%(8/10vs.0%(0/5)。方案与方案的总体抢救率为94%(287)。76%(41)偏离方案(p<0.001,Cochran-Mantel-Haenszel检验)。在318例接受血管造影的患者中,仅有8例发生并发症(2%)。其中包括5个通路并发症和3个脓肿。
    结论:对于非手术治疗的所有严重脾损伤,使用需要常规脾动脉栓塞的方案是安全的,并发症发生率非常低。与非SAE患者相比,具有脾血管栓塞失败率的NOM在所有较高等级的损伤中都得到了改善。因此,对于所有血液动力学稳定的所有高级类型的患者,应将SAE视为此类损伤的主要治疗形式。
    OBJECTIVE: Nonoperative management (NOM) of blunt splenic injury (BSI) is well accepted in appropriate patients. Splenic artery embolization (SAE) in higher-grade injuries likely plays an important role in increasing the success of NOM. We previously implemented a protocol requiring referral of all BSI grades III-V undergoing NOM for SAE. It is unknown the risk of complications as well as longitudinal outcomes. We aimed to examine the splenic salvage rate and safety profile of the protocol. We hypothesized the splenic salvage rate would be high and complications would be low.
    METHODS: A retrospective study was performed at our Level 1 trauma center over a 9-year period. Injury characteristics and outcomes in patients sustaining BSI grades III-V were collected. Outcomes were compared for NOM on protocol (SAE) and off protocol (no angiography or angiography but no embolization). Complications for angiographies were examined.
    RESULTS: Between January 2010 and February 2019, 570 patients had grade III-V BSI. NOM was attempted in 359 (63 %) with overall salvage rate of 91 % (328). Of these, 305 were on protocol while 54 were off protocol (41 no angiography and 13 angiography but no SAE). During the study period, for every grade of injury a pattern was seen of a higher salvage rate in the on-protocol group when compared to the off-protocol group (Grade III, 97 %(181/187) vs. 89 %(32/36), Grade IV, 91 %(98/108) vs. 69 %(9/13) and Grade V, 80 %(8/10 vs. 0 %(0/5). The overall salvage rate was 94 %(287) on protocol vs. 76 %(41) off protocol (p < 0.001, Cochran-Mantel-Haenszel test). Complications occurred in only 8 of the 318 who underwent angiography (2 %). These included 5 access complications and 3 abscesses.
    CONCLUSIONS: The use of a protocol requiring routine splenic artery embolization for all high-grade spleen injuries slated for non-operative management is safe with a very low complication rate. NOM with splenic angioembolization failure rate is improved as compared to non-SAE patients\' at all higher grades of injury. Thus, SAE for all hemodynamically stable patients of all high-grade types should be considered as a primary form of therapy for such injuries.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    OBJECTIVE: To compare the clinical effect of intradermal needling and acupuncture in prevention and treatment of leukopenia after chemotherapy with spleen-kidney deficiency.
    METHODS: A total of 90 patients with malignant tumor who received chemotherapy were randomly divided into a intradermal needling group (30 cases, 1 case dropped out), an acupuncture group (30 cases, 2 cases dropped out, 1 case was eliminated) and a control group (30 cases). The control group received conventional symptomatic treatment after chemotherapy. On the basis of the treatment in the control group, the intradermal needling group received intradermal needling at Guanyuan (CV 4), Dazhui (GV 14) and bilateral Geshu (BL 17), Zusanli (ST 36),Shenshu (BL 23), the needles were retained for 48 h, once every other day. On the basis of the treatment in the control group, the acupuncture group received conventional acupuncture at the same acupoints as the intradermal needling group, once every other day. The treatment started from the first day of chemotherapy, for a total of 2 weeks in the three groups. The white blood cell count, neutrophil count, hemoglobin content, platelet count and Karnofsky performance status (KPS) score before treatment and on 3rd, 7th, 14th, and 21st days after treatment were compared among the three groups. The incidence and grading of leukopenia and the usage of leukocyte-boosting drug during chemotherapy cycle was recorded.
    RESULTS: On 7th day after treatment, the white blood cell count in the intradermal needling group and the acupuncture group was higher than that in the control group (P<0.01, P<0.05). On the 14th day after treatment, the hemoglobin content in the intradermal needling group and the acupuncture group was higher than that in the control group (P<0.01). On the 7th, 14th, and 21st days after treatment, the platelet count in the acupuncture group was higher than that in the control group (P<0.01), on the 14th and 21st days after treatment, the platelet count in the intradermal needling group was higher than that in the control group (P<0.01). There was no statistically significant difference among the three groups after treatment in terms of neutrophil count, KPS score, incidence and grading of leukopenia, and the usage of leukocyte-boosting drug (P>0.05).
    CONCLUSIONS: Both intradermal needling and acupuncture can effectively increase peripheral blood white blood cell count, hemoglobin content and platelet count during chemotherapy cycle, reduce the toxicity of chemotherapy drug to bone marrow hematopoietic function, and alleviate bone marrow suppression after chemotherapy. The two treatments are equally effective.
    目的:比较揿针和针刺防治脾肾两虚型化疗后白细胞减少症的临床疗效。方法:将90例接受化疗的恶性肿瘤患者随机分为揿针组(30例,脱落1例)、针刺组(30例,脱落2例,剔除1例)和对照组(30例)。对照组在化疗的基础上予常规对症治疗;在对照组治疗基础上,揿针组于关元、大椎及双侧膈俞、足三里、肾俞行揿针治疗,留针48 h,隔日1次;在对照组治疗基础上,针刺组于揿针组相同穴位行常规针刺治疗,隔日1次。均从化疗第1天开始,共治疗2周。比较各组患者治疗前及治疗第3、7、14、21天白细胞计数、中性粒细胞计数、血红蛋白含量、血小板计数、Karnofsky功能状态(KPS)评分;于治疗第21天评定白细胞减少症的分度、发生率,记录化疗周期中升白细胞药物使用情况。结果:治疗第7天,揿针组和针刺组白细胞计数高于对照组(P<0.01,P<0.05)。治疗第14天,揿针组和针刺组血红蛋白含量高于对照组(P<0.01)。治疗第7、14、21天,针刺组血小板计数高于对照组(P<0.01),治疗第14、21天,揿针组血小板计数高于对照组(P<0.01)。各组治疗后各时间点中性粒细胞计数、KPS评分及白细胞减少症分度、白细胞减少症发生率、升白细胞药物使用情况比较,差异无统计学意义(P>0.05)。结论:揿针和常规针刺在化疗周期中均可升高外周血白细胞计数、血红蛋白含量、血小板计数,减少化疗药物对骨髓造血功能的影响,减轻化疗后骨髓抑制,两种治疗方法疗效相当。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    包含草药配方的传统中药(TCM)已经使用了数千年来治疗各种疾病,比如失眠,基于不同的综合征类型。尽管在动物模型中已提出中药通过肠道菌群调节对失眠有效,人类研究仍然有限。因此,这项研究采用机器学习和整合网络技术来阐明肠道微生物组在两种中药配方-补中益气汤(CSQBD)和健脾益阴清热汤(STYHCD)-治疗被诊断为脾气不足和脾气虚胃热的失眠患者的疗效中的作用。
    纳入63例具有这两种特定中医证型的失眠患者,并接受CSQBD或STYHCD治疗4周。每2周使用匹兹堡睡眠质量指数(PSQI)和失眠严重程度指数(ISI)评估睡眠质量。此外,通过16SrRNA基因测序评估了肠道微生物群的变化。在治疗前和治疗后测量应激和炎症标志物。
    在基线时,仅表现出脾气虚的患者表现出轻微的严重失眠,较低的IFN-α水平,皮质醇水平高于脾气虚胃热者。尽管对PSQI进行了基线调整,但两种中医证型均显示出不同的肠道微生物组特征,ISI,和IFN-α评分。巢式分层10倍交叉验证随机森林分类器显示脾气虚型患者长双歧杆菌丰度高于脾气虚型胃热型患者,与血浆IFN-α浓度呈负相关。CSQBD和STYHCD治疗在2周内均显着改善了睡眠质量,持续了整个研究。此外,治疗后肠道微生物组和炎症标志物发生显著改变.纵向综合网络分析揭示了睡眠质量之间的相互联系,肠道微生物,如相低温芽孢杆菌和Ruminococcaceae,和炎症标志物。
    这项研究揭示了与不同中医证型相关的独特微生物组特征,并强调了肠道微生物组和中药配方在改善失眠方面的功效之间的联系。这些发现加深了我们对与失眠有关的肠-脑轴的理解,并为利用中药草药的精确治疗方法铺平了道路。
    UNASSIGNED: Traditional Chinese medicine (TCM) comprising herbal formulas has been used for millennia to treat various diseases, such as insomnia, based on distinct syndrome types. Although TCM has been proposed to be effective in insomnia through gut microbiota modulation in animal models, human studies remain limited. Therefore, this study employs machine learning and integrative network techniques to elucidate the role of the gut microbiome in the efficacies of two TCM formulas - center-supplementing and qi-boosting decoction (CSQBD) and spleen-tonifying and yin heat-clearing decoction (STYHCD) - in treating insomnia patients diagnosed with spleen qi deficiency and spleen qi deficiency with stomach heat.
    UNASSIGNED: Sixty-three insomnia patients with these two specific TCM syndromes were enrolled and treated with CSQBD or STYHCD for 4 weeks. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) every 2 weeks. In addition, variations in gut microbiota were evaluated through 16S rRNA gene sequencing. Stress and inflammatory markers were measured pre- and post-treatment.
    UNASSIGNED: At baseline, patients exhibiting only spleen qi deficiency showed slightly lesser severe insomnia, lower IFN-α levels, and higher cortisol levels than those with spleen qi deficiency with stomach heat. Both TCM syndromes displayed distinct gut microbiome profiles despite baseline adjustment of PSQI, ISI, and IFN-α scores. The nested stratified 10-fold cross-validated random forest classifier showed that patients with spleen qi deficiency had a higher abundance of Bifidobacterium longum than those with spleen qi deficiency with stomach heat, negatively associated with plasma IFN-α concentration. Both CSQBD and STYHCD treatments significantly improved sleep quality within 2 weeks, which lasted throughout the study. Moreover, the gut microbiome and inflammatory markers were significantly altered post-treatment. The longitudinal integrative network analysis revealed interconnections between sleep quality, gut microbes, such as Phascolarctobacterium and Ruminococcaceae, and inflammatory markers.
    UNASSIGNED: This study reveals distinct microbiome profiles associated with different TCM syndrome types and underscores the link between the gut microbiome and efficacies of Chinese herbal formulas in improving insomnia. These findings deepen our understanding of the gut-brain axis in relation to insomnia and pave the way for precision treatment approaches leveraging TCM herbal remedies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    抑郁症目前是全球第四大残疾原因,影响了大约20%的世界人口。我们建立了慢性束缚应激(CRS)诱导的小鼠抑郁模型,并使用氟西汀作为参考药物。我们评估了藏红花精油(SEO)的治疗潜力,并通过行为指数和基于NMR的代谢组学分析阐明了其潜在机制。研究结果表明,SEO改善了抑郁症的行为症状,例如进入中心区域的数量,粪便计数,延迟到不动,以及尾部悬吊试验(TST)和强制游泳试验(FST)中的不动持续时间,以及纠正5-羟色胺的失调。代谢组学研究确定了肝脏中的16种潜在生物标志物,脾,脾还有肾脏.SEO特别调节了这些生物标志物中的9种:二甲基甘氨酸,甘油,腺苷,β-葡萄糖,α-葡萄糖,尿苷,甘露糖,肌氨酸,和天冬氨酸,甘油成为肝脏和脾脏中常见的生物标志物。通路分析表明这些生物标志物参与糖酵解,甘氨酸丝氨酸苏氨酸代谢,和能量代谢,可能暗示在神经调节中的作用。总之,SEO有效缓解CRS小鼠的抑郁样行为,主要通过糖酵解的调节,氨基酸代谢,和能量代谢,并可能通过神经调节发挥抗抑郁作用。我们的研究通过代谢组学透镜提供了CRS小鼠小分子代谢物改变的见解,为植物精油的抗抑郁潜力提供证据,并有助于我们了解中药治疗抑郁症的机制。
    Depression currently ranks as the fourth leading cause of disability globally, affecting approximately 20% of the world\'s population. we established a chronic restraint stress (CRS) induced depression model in mice and employed fluoxetine as a reference drug. We assessed the therapeutic potential of saffron essential oil (SEO) and elucidated its underlying mechanisms through behavioral indices and NMR-based metabolomic analysis. The findings indicate that SEO ameliorates behavioral symptoms of depression, such as the number of entries into the central area, fecal count, latency to immobility, and duration of immobility in both the Tail Suspension Test (TST) and the Forced Swim Test (FST), along with correcting the dysregulation of 5-serotonin. Metabolomic investigations identified sixteen potential biomarkers across the liver, spleen, and kidneys. SEO notably modulated nine of these biomarkers: dimethylglycine, glycerol, adenosine, β-glucose, α-glucose, uridine, mannose, sarcosine, and aspartate, with glycerol emerging as a common biomarker in both the liver and spleen. Pathway analysis suggests that these biomarkers participate in glycolysis, glycine serine threonine metabolism, and energy metabolism, potentially implicating a role in neural regulation. In summary, SEO effectively mitigates depressive-like behaviors in CRS mice, predominantly via modulation of glycolysis, amino acid metabolism, and energy metabolism, and potentially exerts antidepressant effects through neural regulation. Our study offers insights into small molecule metabolite alterations in CRS mice through a metabolomics lens, providing evidence for the antidepressant potential of plant essential oils and contributing to our understanding of the mechanisms of traditional Chinese medicine in treating depression.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    弓形虫是一种细胞内原生动物寄生虫,感染除红细胞外的所有有核细胞。目前,核酸疫苗在弓形虫控制中被广泛研究,和几种核酸疫苗候选抗原在各种研究中显示出良好的保护作用。本研讨旨在构建以弓形虫SRS29C为靶基因的核酸疫苗。我们探索了弓形虫表面蛋白SRS29C以及SRS29C和SAG1的组合基因的核酸疫苗,并评估了其对弓形虫的免疫保护作用。为了扩增基因片段并将其克隆到表达载体中,通过PCR构建重组质粒pEGFP-SRS29C。用质粒转染真核细胞,并使用Westernblot方法评估靶蛋白的表达。ELISA法测定血清IgG水平,用CCK-8法检测脾淋巴细胞增殖能力。通过流式细胞术测量CD4+和CD8+T细胞的百分比。用单基因核酸疫苗和组合疫苗免疫小鼠三次。使用ELISA试剂盒测定脾淋巴细胞细胞因子表达。在体内昆虫攻击实验期间,监测并记录小鼠的存活时间,并评估了疫苗的保护能力。结果显示,SRS29C基因片段的PCR扩增是成功的。4,733-bp的载体片段和1,119-bp的目标片段均通过双重消化被识别。此外,转染重组质粒pEGFP-SRS29C后,所提取的蛋白质的蛋白质印迹检查显示存在66kDa的靶蛋白质条。试验结果表明,pEGFP-SRS29C组和共免疫组血清中IgG含量显著高于PBS组和空载体组。联合免疫组诱导的IgG效价高于pEGFP-SRS29C组和pEGFP-SAG1组,脾淋巴细胞增殖数高于PBS组和空载体组。CD4+/CD8+T比值高于PBS组和空载体组。抗原刺激后,pEGFP-SRS29C组和联合免疫组的脾细胞中IFN-γ和TNF-α的表达显着升高。在蠕虫攻击实验中,PBS和空载体组中的小鼠在蠕虫攻击后9天内死亡,而pEGFP-SRS29C组小鼠存活18天,pEGFP-SAG1组小鼠存活21天,联合免疫组小鼠存活24天。这说明构建的弓形虫核酸疫苗pEGFP-SRS29C和联合基因疫苗能够诱导小鼠产生一定的体液和细胞免疫应答,增强其抵抗弓形虫感染的能力。
    Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice\'s survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine\'s protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:评估经皮脾穿刺(PTSA)对PV病患者进行门静脉(PV)干预的安全性和有效性。
    方法:如果需要进行PV血管成形术的经皮导管插入术,则纳入患有PV疾病的成年患者,栓塞,血栓切除术,静脉曲张栓塞,或经颈静脉肝内门体分流术(TIPS)放置困难的TIPS或慢性闭塞PV的再通。该程序在2018年1月至2023年1月之间进行。如果患者有活动性感染,则将其排除在外,有一个慢性阻塞脾静脉恶性针道浸润,做了脾切除术,或未满18岁。
    结果:30名患者(15名女性,15名男子)报名参加。30例患者中的29例(96.7%)通过PTSA成功进行了PV的导管插入。30例患者中5例(16.7%)的主要不良反应为腰痛。没有脾脏出血事件,脾静脉,或记录经皮接入点。报告肝出血和肺静脉再血栓各2例(6.7%),和血红蛋白水平的变化(平均值[SD],-0.5[1.4]g/dL)记录在14例(46.7%)中。
    结论:PTSA作为访问PV的方法是安全且可实现的,并发症的风险最小。通过使用管道闭合方法,最小到没有出血是可能的。
    OBJECTIVE: To assess the safety and effectiveness of percutaneous transsplenic access (PTSA) for portal vein (PV) interventions among patients with PV disease.
    METHODS: Adult patients with PV disease were enrolled if they required percutaneous catheterization for PV angioplasty, embolization, thrombectomy, variceal embolization, or transjugular intrahepatic portosystemic shunt (TIPS) placement for a difficult TIPS or recanalization of a chronically occluded PV. The procedures were performed between January 2018 and January 2023. Patients were excluded if they had an active infection, had a chronically occluded splenic vein malignant infiltration of the needle tract, had undergone splenectomy, or were under age 18 years.
    RESULTS: Thirty patients (15 women, 15 men) were enrolled. Catheterization of the PV through PTSA succeeded for 29 of 30 patients (96.7%). The main adverse effect recorded was flank pain in 5 of 30 cases (16.7%). No bleeding events from the spleen, splenic vein, or percutaneous access point were recorded. Two cases (6.7%) each of hepatic bleeding and rethrombosis of the PV were reported, and a change in hemoglobin levels (mean [SD], - 0.5 [1.4] g/dL) was documented in 14 cases (46.7%).
    CONCLUSIONS: PTSA as an approach to accessing the PV is secure and achievable, with minimal risk of complications. Minimal to no bleeding is possible by using tract closure methods.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    在这项研究中,研究了纳米零价铁(nZVI)和涂有柠檬酸和三磷酸钠的nZVI(CA-nZVI和STPP-nZVI)在小鼠中的分布和毒性。nZVIs主要在肝脏和脾脏中发现,其次是肺,心,还有肾脏.组织学分析显示,除第14天的肝脏外,所有器官均无明显的组织病理学异常或病变。nZVI对小鼠的体重或其器官的重量没有明显的影响。与对照组相比,nZVIs组血液学指标无显著变化.然而,nZVIs组表现出不同水平的丙氨酸转氨酶升高,天冬氨酸转氨酶,和肌酐,提示小鼠肝脏和肾脏炎症。nZVIs组中核因子红系2相关因子2和血红素加氧酶1的上调可能是对nZVIs诱导的氧化应激的反应。免疫组织化学分析证实了三个nZVI组诱导的炎症反应。螯合剂对nZVIs在小鼠中的分布或毒性没有显著影响。这项研究有助于全面而详细地了解nZVI在环境领域的毒性。
    In this study, the distribution and toxicity of nanoscale zero valent iron (nZVI) and nZVIs coated with citric acid and sodium tripolyphosphate (CA-nZVI and STPP-nZVI) in mice were investigated. nZVIs were primarily found in the livers and spleens, followed by the lungs, hearts, and kidneys. Histologic analysis revealed no significant histopathologic abnormalities or lesions in all organs except the liver at 14th d gavage. nZVIs did not have a noticeable impact on the body weight of the mice or the weight of their organs. Compared with the control group, there were no significant changes in hematology indexes in the nZVIs groups. However, the nZVIs groups exhibited varying levels of elevation in alanine aminotransferase, aspartate aminotransferase, and creatinine, suggesting liver and kidney inflammation in mice. The up-regulation of Nuclear Factor erythroid 2-Related Factor 2 and Heme oxygenase 1 in the nZVIs groups may be a response to nZVIs-induced oxidative stress. Immunohistochemical analysis confirmed the inflammatory response induced by the three nZVI groups. Chelating agents did not have a significant impact on the distribution or toxicity of nZVIs in mice. This study contributes to a comprehensive and detailed insight into nZVI toxicity in the environmental field.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    脾虚可导致脾脏的各种生理功能异常。白术(AMR)是一种用于健脾补气的中药。本研究旨在通过谱效关系和化学计量学来确定影响AMR健脾益气功效的主要活性成分。运用网络药理学研究AMR健脾益气的作用机制,分子对接用于验证目的。研究结果表明,麸皮油炸AMR表现出优异的疗效,其中白曲烯醇和白曲酮被确定为主要活性成分。AtractylenolideII成为影响AMR有效性的最有影响力的成分,而关键靶标是雄激素受体。此外,涉及的关键途径包括丝裂原活化蛋白级联(MAPK)级联,RNA聚合酶II转录因子活性,配体激活的序列特异性DNA结合,和RNA聚合酶II序列特异性DNA结合转录因子结合。总之,我们的研究确定了与AMR疗效相关的主要活性成分,并对其作用机制进行了初步探索.这为未来研究AMR药效学的物质基础和分子机制提供了理论基础。
    Spleen deficiency can lead to various abnormal physiological functions of the spleen. Atractylodis Macrocephalae Rhizoma (AMR) is a traditional Chinese medicine used to invigorate the spleen and tonify qi. The study aimed to identify the primary active components influencing the efficacy of AMR in strengthening the spleen and replenishing qi through spectrum-effect relationship and chemometrics. Network pharmacology was used to investigate the mechanism by which AMR strengthens the spleen and replenishes qi, with molecular docking utilized for validation purposes. The findings indicated that bran-fried AMR exhibited superior efficacy, with atractylenolides and atractylone identified as the primary active constituents. Atractylenolide II emerged as the most influential component impacting the effectiveness of AMR, while the key target was androgen receptor. Furthermore, crucial pathways implicated included the mitogen-activated protein cascade (MAPK) cascade, RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding, and RNA polymerase II sequence-specific DNA-binding transcription factor binding. In summary, our study has identified the primary active components associated with the efficacy of AMR and has provided an initial exploration of its mechanism of action. This offers a theoretical foundation for future investigations into the material basis and molecular mechanisms underlying the pharmacodynamics of AMR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Clinical Trial
    本研究的目的是通过基于UHPLC-Q-TOF/MS的代谢组学方法验证柴胡桂枝甘姜汤(CGGD)治疗慢性非萎缩性胃炎(CNAG)伴胆囊热脾冷综合征(GHSC)的有效性并探讨其作用机制。
    进行了一项观察性对照前后研究,以验证CGGD在2023年1月至6月用GHSC治疗CNAG的有效性,招募了27名患者,服用CGGD28天。30名健康志愿者作为对照。通过比较中医证候和CNAG评分评价疗效,治疗前后的临床参数。采用ELISA法采集血浆中与胃肠功能相关的激素水平。使用基于UHPLC-Q-TOF/MS的代谢组学方法探索CGGD用GHSC治疗CNAG的机制。
    接受CGGD治疗的患者在中医证候和CNAG评分方面有统计学上的显着改善(p<0.01)。CGGD治疗引起了15种生物标志物的浓度变化,富含甘油磷脂代谢,和支链氨基酸的生物合成途径。此外,CGGD治疗减轻了胃肠激素水平的异常,并显着增加了胃蛋白酶原水平。
    该临床试验首次提供了有关临床参数的详细数据,这些数据证明了CGGD在治疗CNAG伴GHSC患者中的有效性。这项研究还提供了支持性证据,表明CNAG与GHSC患者的支链氨基酸代谢和甘油磷脂水平紊乱有关。提示基于中医证候积分的CNAG治疗是合理的,也为CGGD提供了潜在的药理作用机制。
    UNASSIGNED: The aim of this study was to verify the effectiveness and explore the mechanism of Chaihu-Guizhi-Ganjiang decoction (CGGD) in the treatment of chronic non-atrophic gastritis (CNAG) with gallbladder heat and spleen cold syndrome (GHSC) by metabolomics based on UHPLC-Q-TOF/MS.
    UNASSIGNED: An observational controlled before-after study was conducted to verify the effectiveness of CGGD in the treatment of CNAG with GHSC from January to June 2023, enrolling 27 patients, who took CGGD for 28 days. 30 healthy volunteers were enrolled as the controls. The efficacy was evaluated by comparing the traditional Chinese medicine (TCM) syndrome and CNAG scores, and clinical parameters before and after treatment. The plasma levels of hormones related to gastrointestinal function were collected by ELISA. The mechanisms of CGGD in the treatment of CNAG with GHSC were explored using a metabolomic approach based on UHPLC-Q-TOF/MS.
    UNASSIGNED: Patients treated with CGGD experienced a statistically significant improvement in TCM syndrome and CNAG scores (p < 0.01). CGGD treatment evoked the concentration alteration of 15 biomarkers, which were enriched in the glycerophospholipid metabolism, and branched-chain amino acids biosynthesis pathways. Moreover, CGGD treatment attenuated the abnormalities of the gastrointestinal hormone levels and significantly increased the pepsinogen level.
    UNASSIGNED: It was the first time that this clinical trial presented detailed data on the clinical parameters that demonstrated the effectiveness of CGGD in the treatment of CNAG with GHSC patients. This study also provided supportive evidence that CNAG with GHSC patients were associated with disturbed branched-chain amino acid metabolism and glycerophospholipid levels, suggesting that CNAG treatment based on TCM syndrome scores was reasonable and also provided a potential pharmacological mechanism of action of CGGD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号